Three reasons: (1) Drug pricing — NMPA-approved biologics for IBD (anti-TNF, vedolizumab, ustekinumab, risankizumab, mirikizumab, upadacitinib) at NMPA-listed prices substantially below US, with biosimilar availability for adalimumab and infliximab; (2) Volume — Class A IBD centres operate at scale with structured MDT clinics and trial leadership; (3) Trial access — China hosts active trials of next-generation biologics, S1P modulators (etrasimod, ozanimod biosimilars), advanced JAK selectivity (deucravacitinib), and IBD-specific cell therapies.

What does a comprehensive IBD workup include?

Standard 3–5 day pathway: gastroenterology consult; ileocolonoscopy with biopsy (8+ biopsies for histology); MR enterography (MRE) for small bowel imaging; fecal calprotectin and lactoferrin; comprehensive labs (CBC, CMP, ESR, CRP, ferritin, vitamin D, vitamin B12); infectious workup (C. difficile, HBV, HCV, HIV, TB before biologic); endoscopic activity scoring (Mayo for UC, SES-CD for Crohn's); bilingual final report mapped to AGA / ECCO / Chinese IBD guidelines.

Can I start a biologic in China?

Yes — common workflow. Pre-biologic workup (TB IGRA, hepatitis screen, baseline labs) at the partner centre; induction infusion or first injection administered (typically 3 doses over 6 weeks for infliximab; 2 loading doses for adalimumab; 1 IV induction for vedolizumab / ustekinumab / risankizumab); subsequent maintenance dosing self-administered or via home gastroenterology team. Long-term continuity depends on home-country approval and reimbursement of the chosen agent.

What about IBD surgery?

Comprehensive surgical IBD program at top centres: ileal pouch-anal anastomosis (IPAA) for refractory UC — laparoscopic and robotic available; ileocecal resection and small bowel resection for stricturing Crohn's; strictureplasty for short strictures preserving bowel length; perianal Crohn's surgery (seton, fistulotomy, LIFT) at IBD specialty centres. Indicative pricing: 2-stage IPAA $18,000–$28,000; ileocecal resection $11,000–$16,000; complex Crohn's reoperation $20,000–$35,000. MDT review with gastroenterology + surgery before complex resection.

What about emerging therapies?

Active in China: S1P modulators (ozanimod NMPA-approved 2023; etrasimod approval pending); selective JAK1 inhibitors (upadacitinib NMPA-approved); IL-23p19 inhibitors (risankizumab NMPA-approved; mirikizumab NMPA-approved 2024); fecal microbiota transplantation in selected academic centres; cell therapies in trial settings. Patient selection across these requires individual gastroenterology review.

What about diet and microbiome therapy?

Dietary therapy: exclusive enteral nutrition (EEN) for pediatric Crohn's induction has good evidence; specific carbohydrate diet, low-FODMAP and Mediterranean diet have evidence as adjuncts. Fecal microbiota transplant (FMT) for UC has Cochrane-supported moderate evidence; available in select Chinese academic centres for mild-moderate UC. We position dietary and FMT therapy as evidence-supported adjuncts; biologics remain the standard of care for moderate-severe disease.

Gastroenterology · 2026

IBD treatment in China,
biologics + JAK at NMPA prices.

Comprehensive ulcerative colitis and Crohn's disease management with NMPA-approved biologics (anti-TNF, vedolizumab, ustekinumab, risankizumab, mirikizumab) and JAK inhibitors. Class A IBD centres with surgical and trial pathways.

Get a written quote Top IBD centres

$850–1,800

IBD workup

Colonoscopy + MRE + bilingual report

Partner clinic quotes 2024

Biologics

Full menu NMPA

Anti-TNF, vedolizumab, ustekinumab, risankizumab, mirikizumab, upadacitinib

NMPA approvals

$320–680 / mo

Vedolizumab / ustekinumab

vs $4,500–8,000 / month in the US

NMPA listings

Surgical

MIS IPAA + ileostomy

Robotic and laparoscopic options at top centres

Centre programs

Class A

IBD centres

PUMC, Beijing Friendship, Renji, Sun Yat-sen IBD

NHC ratings

Bilingual

Workup + plan

Standard discharge package + home-team handover

Service standard

Tiers & pricing

Six tiers, transparent pricing.

Step 1

IBD diagnostic workup

Colonoscopy with biopsy, MRE for small bowel, fecal calprotectin, comprehensive labs, bilingual report.

$850–1,800

First-line

Anti-TNF biologics

Adalimumab, infliximab (originator + biosimilars). Workup + induction + handover.

$220–550 / month

Gut-selective

Vedolizumab

Anti-α4β7 integrin. Lower systemic infection risk; for moderate-severe UC and Crohn's.

$320–680 / month

Newer biologic

IL-12/23 + IL-23 biologics

Ustekinumab, risankizumab, mirikizumab. For moderate-severe UC and Crohn's.

$420–850 / month

Oral

JAK inhibitors

Tofacitinib, upadacitinib for moderate-severe UC. Boxed warning patient selection.

$280–650 / month

Surgical

IBD surgery

Total proctocolectomy with IPAA for refractory UC; resection + strictureplasty for Crohn's.

$11,000–22,000

Top hospitals

Six centres
open to international patients.

Beijing

PUMC IBD Center 北京协和医院

Academic IBD centre · diagnostic excellence · complex case program

Beijing

Beijing Friendship Hospital IBD 北京友谊医院

Class A · National Clinical Research Center for Digestive Diseases · IBD trial leader

Shanghai

Renji Hospital IBD 仁济医院

Class A · large IBD cohort · biologic and surgical pathway integration

Shanghai

Zhongshan Hospital IBD 中山医院

Class A · MDT IBD program · gastroenterology + surgery + radiology

Guangzhou

Sun Yat-sen Sixth Affiliated Hospital 中山六院

Class A · regional reference for IBD · large surgical IBD volume

Multi-city

United Family Hospitals 和睦家

JCI · expat-focused · routine IBD follow-up · biologic infusion

FAQ

Frequently asked questions.

Why China for IBD?: Three reasons: (1) Drug pricing — NMPA-approved biologics for IBD (anti-TNF, vedolizumab, ustekinumab, risankizumab, mirikizumab, upadacitinib) at NMPA-listed prices substantially below US, with biosimilar availability for adalimumab and infliximab; (2) Volume — Class A IBD centres operate at scale with structured MDT clinics and trial leadership; (3) Trial access — China hosts active trials of next-generation biologics, S1P modulators (etrasimod, ozanimod biosimilars), advanced JAK selectivity (deucravacitinib), and IBD-specific cell therapies.
What does a comprehensive IBD workup include?: Standard 3–5 day pathway: gastroenterology consult; ileocolonoscopy with biopsy (8+ biopsies for histology); MR enterography (MRE) for small bowel imaging; fecal calprotectin and lactoferrin; comprehensive labs (CBC, CMP, ESR, CRP, ferritin, vitamin D, vitamin B12); infectious workup (C. difficile, HBV, HCV, HIV, TB before biologic); endoscopic activity scoring (Mayo for UC, SES-CD for Crohn's); bilingual final report mapped to AGA / ECCO / Chinese IBD guidelines.
Can I start a biologic in China?: Yes — common workflow. Pre-biologic workup (TB IGRA, hepatitis screen, baseline labs) at the partner centre; induction infusion or first injection administered (typically 3 doses over 6 weeks for infliximab; 2 loading doses for adalimumab; 1 IV induction for vedolizumab / ustekinumab / risankizumab); subsequent maintenance dosing self-administered or via home gastroenterology team. Long-term continuity depends on home-country approval and reimbursement of the chosen agent.
What about IBD surgery?: Comprehensive surgical IBD program at top centres: ileal pouch-anal anastomosis (IPAA) for refractory UC — laparoscopic and robotic available; ileocecal resection and small bowel resection for stricturing Crohn's; strictureplasty for short strictures preserving bowel length; perianal Crohn's surgery (seton, fistulotomy, LIFT) at IBD specialty centres. Indicative pricing: 2-stage IPAA $18,000–$28,000; ileocecal resection $11,000–$16,000; complex Crohn's reoperation $20,000–$35,000. MDT review with gastroenterology + surgery before complex resection.
What about emerging therapies?: Active in China: S1P modulators (ozanimod NMPA-approved 2023; etrasimod approval pending); selective JAK1 inhibitors (upadacitinib NMPA-approved); IL-23p19 inhibitors (risankizumab NMPA-approved; mirikizumab NMPA-approved 2024); fecal microbiota transplantation in selected academic centres; cell therapies in trial settings. Patient selection across these requires individual gastroenterology review.
What about diet and microbiome therapy?: Dietary therapy: exclusive enteral nutrition (EEN) for pediatric Crohn's induction has good evidence; specific carbohydrate diet, low-FODMAP and Mediterranean diet have evidence as adjuncts. Fecal microbiota transplant (FMT) for UC has Cochrane-supported moderate evidence; available in select Chinese academic centres for mild-moderate UC. We position dietary and FMT therapy as evidence-supported adjuncts; biologics remain the standard of care for moderate-severe disease.

Related guides

Colonoscopy

IBD diagnosis and surveillance with AI-assisted detection.

Read the guide

Colorectal Cancer

IBD-associated cancer surveillance and treatment.

Read the guide

Autoimmune Disease

Comprehensive autoimmune disease care including biologics.

Read the guide

Clinical Trials

Trial screening for refractory IBD and emerging therapies.

Read the guide

Records Translation

Bilingual gastroenterology, pathology and biologic prescription.

Read the guide

Second Opinion

Independent IBD specialist second opinion from $250.

Read the guide

Send your colonoscopy + MRE
for an IBD plan.

Upload your endoscopy report, biopsy histology, MRE and current medication. We return a written plan from a partner gastroenterologist — including biologic / JAK selection, surgical considerations and trial eligibility if applicable.

Request a quote See cost comparison

This page is for general information only and does not constitute medical advice. Acute severe IBD with toxic megacolon, perforation, or massive bleeding is a medical emergency — do not travel.

IBD treatment in China,biologics + JAK at NMPA prices.

Six tiers, transparent pricing.

IBD diagnostic workup

Anti-TNF biologics

Vedolizumab

IL-12/23 + IL-23 biologics

JAK inhibitors

IBD surgery

Six centresopen to international patients.

PUMC IBD Center 北京协和医院

Beijing Friendship Hospital IBD 北京友谊医院

Renji Hospital IBD 仁济医院

Zhongshan Hospital IBD 中山医院

Sun Yat-sen Sixth Affiliated Hospital 中山六院

United Family Hospitals 和睦家

Frequently asked questions.

Related guides

Colonoscopy

Colorectal Cancer

Autoimmune Disease

Clinical Trials

Records Translation

Second Opinion

Send your colonoscopy + MREfor an IBD plan.

IBD treatment in China,
biologics + JAK at NMPA prices.

Six centres
open to international patients.

Send your colonoscopy + MRE
for an IBD plan.